CASES

Kikuchi-Fujimoto disease: lymphadenopathy in siblings

Allison Stasiuk BSc Pharm, Susan Teschke MD, Gaynor J. Williams MD MPhil, Matthew D. Seftel MD MPH

Patient 1

A 19-year-old Aboriginal woman presented with a three-week history of swollen neck glands, nausea, vomiting, chills and weight loss. On examination, she had bilateral, nontender, diffuse cervical lymphadenopathy. Oral examination revealed extensive dental caries and periodontal disease. The results of her laboratory workup are shown in Table 1. Both a lymph node aspiration and a bone marrow biopsy were nondiagnostic. The patient was scheduled for a surgical lymph node biopsy, but when she was seen one month later, the lymphadenopathy had resolved spontaneously. Based on these findings, she was diagnosed with Kikuchi–Fujimoto disease. At follow-up a year and a half later, she had no evidence of recurrence.

Patient 2

Two years after the initial presentation of the first patient, her 19-year-old younger sister was assessed for a three-week history of swollen neck glands, night sweats, decreased appetite and weight loss. The sister also had severe dental and periodontal disease. A computed tomography (CT) scan of the neck showed severe bilateral lymphadenopathy, with the largest lymph node measuring $2.6 \times 1.2 \times 2.6$ cm. Further CT scans showed moderate lymphadenopathy in the mediastinal, right hilar, axillary and pelvic regions. The results of a laboratory work-up are shown in Table 1. An excisional biopsy of a cervical lymph node and a bone marrow biopsy were done. By one month after presentation, the patient's symptoms and signs had resolved, and she was discharged home. She was also diagnosed with Kikuchi–Fujimoto disease. At follow-up seven months later, she had a normal physical examination and her laboratory test results were normal.

Given that both siblings presented with an uncommon disorder at the same age, human leukocyte antigen (HLA) genotyping was done to examine whether shared immunogenetics may account for a predisposition to this disease. The results are shown in Table 1.

Pathology findings

In both sisters, the results of bone marrow examination were normocellular for all lineages and showed no evidence of myelodysplasia or features of a neoplastic infiltrate. Aspiration

Key points

- Kikuchi–Fujimoto disease is an uncommon and sometimes familial disorder that should be considered in the differential diagnosis of cervical lymphadenopathy.
- Typical presentation includes fever, leukopenia and cervical lymphadenopathy.
- Although Kikuchi–Fujimoto disease is self-limiting and no definitive treatment exists, lymph node biopsy is required to rule out malignancy.
- Patients should be followed closely because of increased risk for recurrence and for systemic lupus erythematosus.

of a cervical lymph node in the first sister was nondiagnostic. In the second sister, an excisional biopsy showed geographic areas of necrosis containing apoptotic bodies and a striking degree of karyorrhexis with nuclear debris (Figure 1). Cells within the areas of necrosis were highly proliferative; more than 60% of the cells tested positive for the Ki-67 proliferation marker. Cellular material included a large number of histiocytes (CD68-positive and myeloperoxidase-positive), some with crescent-shaped nuclei, as well as large transformed lymphocytes (primarily CD8-positive T cells) (Figure 2). No neutrophils and only a few plasma cells were seen. Staining tests for organisms (periodic acid-Schiff reaction, Gömöri methenamine silver stain and Ziehl–Neelsen staining method) were negative. No morphologic evidence of malignancy was seen.

Discussion

Kikuchi–Fujimoto disease is also known as Kikuchi disease or histiocytic necrotizing lymphadenitis. It was first described in Japan by Kikuchi and Fujimoto in 1972, and has now been reported in most regions of the world. Typical presentation includes fever, cervical lymphadenopathy and leukopenia, but may also include night sweats, nausea, vomiting and weight loss.¹ Lymphadenopathy is most commonly cervical (79%), but can include any lymph node region and can be generalized

From the Faculty of Medicine (Stasiuk), the Department of Internal Medicine (Teschke, Seftel), the Department of Pathology (Williams), University of Manitoba, Winnipeg, Man.

CMAJ 2011. DOI:10.1503/cmaj.091347

(Box 1). The median age at presentation is 30 years. Most patients (70%) are young adults, but the disease can occur at almost any age. 12 Reported case series support a female predilec-

Table 1: Results of laboratory investigations in two patients with Kikuchi–Fujimoto disease

Leukocyte count, × 10°/L (normal 4.5–11) 2.8 1.9 Lymphocyte count, × 10°/L (normal 1.0–3.3) 0.88 0.50 Neutrophil count, × 10°/L (normal 1.7–7.6) 1.66 1.30 Platelet count, × 10°/L (normal 1140–440 × 10°/L) 226 244 Hemoglobin (normal 120–160 g/L) 109 107 g/L Mean cell volume (normal 83.7 83.2 80–98 fL) 67 62 ALT (normal 10–32 U/L) 67 62 ALT (normal 30–120 U/L) 76 112 Total bilirubin (normal 3–18 μmol/L) 8 4 LDH (normal < 200 U/L) 1128 1352 ESR (normal 0–30 mm/h) 31 Not performed CMV IgM Negative Negative CMV IgG Positive Not performed Hepatitis C serology Negative Negative Hepatitis C serology Negative Negative Hepatitis B sAg Negative Negative HUV 1/2 serology Negative Negative Bartonella henselae serology Negative Negative <th>Investigation</th> <th>Patient 1</th> <th>Patient 2</th>	Investigation	Patient 1	Patient 2
(normal 1.0–3.3) Neutrophil count, × 10³/L (normal 1.7–7.6) Platelet count, × 10³/L (normal 1.7–7.6) Platelet count, × 10³/L (normal 1.40–440 × 10³/L) Hemoglobin (normal 120–160 g/L) Mean cell volume (normal 83.7 83.2 83.2 AST (normal 10–32 U/L) AST (normal 30–120 U/L) ALP (normal 30–120 U/L) Total bilirubin (normal 3–18 μmol/L) LDH (normal < 200 U/L) ESR (normal 0–30 mm/h) CMV IgM Negative CMV IgG Positive Negative Hepatitis C serology Negative Negative Hepatitis B sAg Negative Not performed Negative Negative Negative Negative Not performed Negative		2.8	1.9
Normal 1.7-7.6 Platelet count, × 10		0.88	0.50
1140-440 × 10 ⁹ /L) Hemoglobin (normal 120-160 g/L) Mean cell volume (normal 83.7 83.2 AST (normal 10-32 U/L) 67 62 ALT (normal 30-120 U/L) 76 112 Total bilirubin (normal 3-18 μmol/L) LDH (normal -200 U/L) 1128 1352 ESR (normal 0-30 mm/h) 31 Not performed CMV IgM Negative Negative CMV IgG Positive Not performed Hepatitis C serology Negative Negative Hepatitis B sAg Negative Negative Hepatitis B sAg Negative Negative Bartonella henselae serology Negative Negative EBV IgM Negative Negative Francisella tularemia serology Negative Negative Francisella tularemia serology Negative Negative Sputum stains for mycobacteria Negative Negative Anti-nuclear antibody Negative Negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Positive SSB (La) antibody NA Positive SNA (Ro) antibody NA Negative SSB (La) antibody NA Negative SIGNA NA Negative	•	1.66	1.30
Mean cell volume (normal 80–98 fL) AST (normal 10–32 U/L) ALT (normal 0–25 U/L) ALP (normal 30–120 U/L) Total bilirubin (normal 3–18 µmol/L) LDH (normal < 200 U/L) IDH (normal 0–30 mm/h) CMV IgM CMV IgG Hepatitis C serology Hepatitis B sAg HIV 1/2 serology Bartonella henselae serology Prancisella tularemia serology Sputum stains for mycobacteria Anti-nuclear antibody SSB (La) antibody SMA Regative SSB (La) antibody RNA Regative Negative Negative Negative Negative Negative Positive (1:160); repeat test negative NA Negative	1,	226	244
80–98 fL)AST (normal 10–32 U/L)6762ALT (normal 0–25 U/L)2918ALP (normal 30–120 U/L)76112Total bilirubin (normal 3–18 μmol/L)84LDH (normal < 200 U/L)		109	107
ALT (normal 0-25 U/L) ALP (normal 30-120 U/L) Total bilirubin (normal 3-18 µmol/L) LDH (normal < 200 U/L) ESR (normal 0-30 mm/h) CMV IgM CMV IgG Hepatitis C serology Hepatitis B sAg HIV 1/2 serology Bartonella henselae serology Francisella tularemia serology Sputum stains for mycobacteria Anti-nuclear antibody SSA (Ro) antibody SSB (La) antibody RNA ROSITIVE SCI-70 antibody HLA-A UA AC 18 4 112 128 1352 135	•	83.7	83.2
ALP (normal 30–120 U/L) Total bilirubin (normal 3–18 µmol/L) LDH (normal < 200 U/L) ESR (normal 0–30 mm/h) CMV IgM CMV IgG Positive Hepatitis C serology Hepatitis B sAg HIV 1/2 serology Bartonella henselae serology Francisella tularemia serology Sputum stains for mycobacteria Anti-nuclear antibody SSA (Ro) antibody SMA ROSITIVE SSB (La) antibody RNA ROSITIVE SCI-70 antibody HLA-A D2 02 02, 31 HLA-CW HLA-DRB1 1352 8 4 4 4 4 4 4 4 4 4 4 4 4	AST (normal 10-32 U/L)	67	62
Total bilirubin (normal 3–18 μmol/L) LDH (normal < 200 U/L) ESR (normal 0–30 mm/h) CMV IgM CMV IgG Positive Hepatitis C serology Hepatitis B sAg HIV 1/2 serology Bartonella henselae serology Francisella tularemia serology Sputum stains for mycobacteria Anti-nuclear antibody SSA (Ro) antibody SMA ROSA RNA ROSA RNA ROSA R	ALT (normal 0–25 U/L)	29	18
µmol/L) LDH (normal < 200 U/L) ESR (normal 0–30 mm/h) CMV IgM CMV IgG Positive Negative Not performed Negative NA Negative Ne	ALP (normal 30-120 U/L)	76	112
ESR (normal 0–30 mm/h) CMV IgM Negative Negative Not performed Negative Not performed Negative Not performed Negative Not performed Negative Nositive NA Negative		8	4
CMV IgM Negative Negative CMV IgG Positive Not performed Hepatitis C serology Negative Negative Hepatitis B sAg Negative Negative Hepatitis B sAg Negative Negative HIV 1/2 serology Negative Negative EBV IgM Negative Negative Bartonella henselae serology Negative Negative Francisella tularemia serology Negative Not performed Sputum stains for mycobacteria Negative Negative Anti-nuclear antibody Negative Positive (1:160); repeat test negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Negative SSB (La) antibody NA Positive SM nantibody NA Positive SCI-70 antibody NA Negative JO-1 antibody NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-CW 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	LDH (normal < 200 U/L)	1128	1352
CMV IgG Positive Not performed Hepatitis C serology Negative Negative Negative Hepatitis B sAg Negative Negative Negative Particles Prancisella tularemia serology Negative Negative Negative Prancisella tularemia serology Negative Negative Negative Prancisella tularemia serology Negative Negative Negative Positive Negative Positive (1:160); repeat test negative Positive Positive Positive Positive Positive Positive Positive Negative SSA (Ro) antibody NA Positive NA Negative Positive Positive Negative Negative Positive NA Negative NA Negative NA Negative NA Positive NA Positive NA Positive NA Positive NA Positive NA Positive NA Negative Negative Negative Negative NA Negative NA Negative NA Negative NA Negative	ESR (normal 0-30 mm/h)	31	Not performed
Hepatitis C serology Hepatitis B sAg Negative SSA (Ro) antibody NA Negative	CMV IgM	Negative	Negative
Hepatitis B sAg Negative Negative HIV 1/2 serology Negative Negative BBV IgM Negative Negative Bartonella henselae serology Negative Negative Francisella tularemia serology Negative Not performed Sputum stains for mycobacteria Negative Negative Anti-nuclear antibody Negative Positive (1:160); repeat test negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Negative SSB (La) antibody NA Positive RNP/Sm antibody NA Positive SCI-70 antibody NA Negative JO-1 antibody NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-CW 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	CMV IgG	Positive	Not performed
HIV 1/2 serology EBV IgM Bartonella henselae serology Francisella tularemia serology Anti-nuclear antibody SSA (Ro) antibody Sm antibody RNP/Sm antibody RNP/Sm antibody Scl-70 antibody MA Degative Negative NA Positive NA Negative	Hepatitis C serology	Negative	Negative
EBV IgM Negative Negative Bartonella henselae serology Negative Negative Francisella tularemia serology Negative Not performed Sputum stains for mycobacteria Negative Negative Anti-nuclear antibody Negative Positive (1:160); repeat test negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Negative Sm antibody NA Positive RNP/Sm antibody NA Positive Scl-70 antibody NA Negative JO-1 antibody NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-CW 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	Hepatitis B sAg	Negative	Negative
Bartonella henselae serologyNegativeNegativeFrancisella tularemia serologyNegativeNot performedSputum stains for mycobacteriaNegativeNegativeAnti-nuclear antibodyNegativePositive (1:160); repeat test negativeSSA (Ro) antibodyNAPositiveSSB (La) antibodyNANegativeSm antibodyNAPositiveRNP/Sm antibodyNAPositiveScl-70 antibodyNANegativeJO-1 antibodyNANegativedsDNANANegativeHLA-A0202, 31HLA-B39, 3539, 51HLA-Cw7, 407, 15HLA-DRB108, 1408, 14	HIV 1/2 serology	Negative	Negative
Francisella tularemia serology Sputum stains for mycobacteria Anti-nuclear antibody Negative Negative Negative Positive (1:160); repeat test negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Negative NA Positive RNP/Sm antibody NA Positive Scl-70 antibody NA Negative JO-1 antibody NA Negative	EBV IgM	Negative	Negative
Sputum stains for mycobacteria Negative Negative Anti-nuclear antibody Negative Positive (1:160); repeat test negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Negative Sm antibody NA Positive RNP/Sm antibody NA Positive Scl-70 antibody NA Negative JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	Bartonella henselae serology	Negative	Negative
Anti-nuclear antibody Negative Positive (1:160); repeat test negative SSA (Ro) antibody NA Negative SSB (La) antibody NA Negative NA RNP/Sm antibody NA Positive Scl-70 antibody NA Negative JO-1 antibody NA Negative NA Negative NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 NA Negative 107, 15	Francisella tularemia serology	Negative	Not performed
repeat test negative SSA (Ro) antibody NA Positive SSB (La) antibody NA Negative NA RNP/Sm antibody NA Positive RNP/Sm antibody NA Negative Scl-70 antibody NA Negative JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 NA Positive NA Negative NA Negative 102 102 103 104 105 105 106 107 107 107 107 107 107 107	Sputum stains for mycobacteria	Negative	Negative
SSB (La) antibody NA Negative NA Positive RNP/Sm antibody NA Positive Scl-70 antibody NA Negative JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	Anti-nuclear antibody	Negative	repeat test
Sm antibody RNP/Sm antibody NA Positive RNP/Sm antibody NA Negative JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	SSA (Ro) antibody	NA	Positive
RNP/Sm antibody NA Positive Scl-70 antibody NA Negative JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	SSB (La) antibody	NA	Negative
Scl-70 antibody NA Negative JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	Sm antibody	NA	Positive
JO-1 antibody NA Negative dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	RNP/Sm antibody	NA	Positive
dsDNA NA Negative HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	Scl-70 antibody	NA	Negative
HLA-A 02 02, 31 HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	JO-1 antibody	NA	Negative
HLA-B 39, 35 39, 51 HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	dsDNA	NA	Negative
HLA-Cw 7, 4 07, 15 HLA-DRB1 08, 14 08, 14	HLA-A	02	02, 31
HLA-DRB1 08, 14 08, 14	HLA-B	39, 35	39, 51
	HLA-Cw	7, 4	07, 15
HLA-DQB1 03 03, 0402	HLA-DRB1	08, 14	08, 14
	HLA-DQB1	03	03, 0402

Note: ALP = alkaline phosphatase, ALT = alanine transaminase, AST = aspartate aminotransferase, CMV = cytomegalovirus, dsDNA = doublestranded deoxyribonucleic acid, EBV = Epstein-Barr virus, ESR = erythrocyte sedimentation rate, HLA = human leukocyte antigen, LDH = lactate dehydrogenase, RNP = ribonucleic protein, Scl = scleroderma, SS = Sjögren syndrome. tion with a male:female ratio ranging from 1:4 to 1:1.3.\(^{1.3}\) The disease is self-limiting, has no definitive treatment and spontaneously resolves within one to four months. The risk of recurrence is 3%–4% and can occur months to years after the initial diagnosis.\(^4\)

The presentation of Kikuchi–Fujimoto disease closely mimics that of lymphoma and is frequently misdiagnosed as such. Patients often undergo extensive investigations for infectious, neoplastic and autoimmune conditions before a diagnosis of Kikuchi–Fujimoto disease is considered. The differential diagnosis for this disease is shown in Box 2.^{1,2} Diagnosis cannot be made using standard laboratory or diagnostic modalities; a lymph node biopsy is required. Histologic criteria for Kikuchi–Fujimoto disease are listed in Box 3.^{1,3,5}

Kikuchi-Fujimoto disease has been found in association with various viruses, bacteria and parasites, but as of yet no




Figure 1: Microscopic view of lymph node biopsy specimen from Patient 2 (hematoxylin and eosin stain, magnification \times 630), showing reactive histiocytes containing darkly stained, spherical karyorrhectic debris (arrows), a lack of neutrophils or malignant cells, and relatively few plasma cells.




Figure 2: Microscopic view of lymph node biopsy specimen from Patient 2 (CD68 stain, magnification \times 200), emphasizing the numerous histiocytes or macrophages with brown staining.

Box 1: Prevalence of the characteristics of Kikuchi-Fujimoto disease¹

- Lymphadenopathy (100%)
- Leukopenia (43%)
- Elevated erythrocyte sedimentation rate (40%)
- Fever (35%)
- Anemia (23%)
- Rash (10%)
- Weight loss (10%)
- Fatigue (7%)
- Joint pain (7%)
- Night sweats, nausea, vomiting or diarrhea (< 7%)

clear causal relation has been shown. ^{1,3,5} Kikuchi–Fujimoto disease shares many characteristics with systemic lupus erythematosus, including similar clinical, epidemiologic and histologic patterns. Patients who have had an episode of Kikuchi–Fujimoto disease may be at increased risk for systemic lupus erythematosus in the future, although the extent of this risk is unknown. ⁶

Human leukocyte antigen genotyping

There are few reported instances of familial Kikuchi–Fujimoto disease or familial associations in the published literature. Human leukocyte antigen (HLA) genotyping for familial Kikuchi–Fujimoto disease has been reported in only one paper. The sisters described in that case share some HLA genotypes as the sisters described here; both of our patients tested positive for HLA-Cw7 and the older sister (Patient 1) also tested positive for HLA-B35. Neither of these genotypes is known to be associated with an increased risk of nonfamilial Kikuchi–Fujimoto disease.

Shared environmental exposure may also explain the coincident diagnosis of Kikuchi–Fujimoto disease in these sisters. Both siblings were from a remote Northern Ontario reserve and were Aboriginal. Given that they both had very poor dentition with associated periodontitis, perioral microorganisms may have triggered the development of this disease. However, no association between oral infection and development of Kikuchi–Fujimoto disease has been reported, so this hypothesis remains to be investigated.

Conclusion

Although uncommon, Kikuchi–Fujimoto disease should be considered in the differential diagnosis of cervical lymphadenopathy. In particular, it can be mistaken for malignant lymphoma. The contribution of genetic or environmental factors to the development of Kikuchi–Fujimoto disease remains unknown. Although the disease is self-limiting, long-term follow-up is important to monitor for recurrence of the disease or development of autoimmune disorders, such as systemic lupus erythematosis.

This article has been peer reviewed.

Competing interests: None declared.

Box 2: Differential diagnosis of cervical lymphadenopathy^{1,2}

Infectious lymphadenitis

- Herpes simplex virus
- Epstein-Barr virus
- Cytomegalovirus
- Cat scratch disease (Bartonella henselae)
- Group A streptococcus infection
- Staphlyococcus aureus infection
- Mycobacterium tuberculosis
- Toxoplasmosis
- Tularemia (Francisella tularenesis)

Neoplasia

- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Metastatic carcinoma

Lymphadenitis of systemic lupus erythematosus

Kawasaki disease

Kikuchi-Fujimoto disease

Box 3: Features of Kikuchi-Fujimoto disease on lymph node biopsy^{1,3,5}

- Erosion of lymphatic tissue
- Circumscribed eosinophilic fibrotic necrotic foci with increased karyorrhexis
- Histiocytes surrounding the necrotic foci
- Nuclear debris
- Increased lymphocytes (predominantly CD8-positive T cells)
- Absence of granulocytes
- · Paucity of plasma cells

REFERENCES

- Kucukardali Y, Solmazgul E, Kunter E, et al. Kikuchi–Fujimoto disease: analysis of 244 cases. Clin Rheumatol 2007;26:50-4.
- Dorfman RF, Berry GJ. Kikuchi's histiocytic necrotizing lymphadenitis: an analysis of 108 cases with emphasis on differential diagnosis. Semin Diagn Pathol 1988;5:329-45.
- Lin HC, Su CY, Huang CC, et al. Kikuchi's disease: a review and analysis of 61 cases. Otolaryngol Head Neck Surg 2003;128:650-3.
- Amir AR, Amr SS, Sheikh SS. Kikuchi–Fujimoto Disease: report of familial occurrence in two human-leukocyte antigen identical non-twin sisters. *J Intern* Med 2002;252:79-83.
- Tsang WY, Chan JK, Ng CS. Kikuchi's lymphadenitis: a morphological analysis
 of 75 cases with special reference to unusual features. Am J Surg Pathol 1994;18:
 219-31.
- El-Ramahi KM, Karrar A, Ali MA. Kikuchi disease and its associations with systemic lupus erythematosus. *Lupus* 1994;3:409-11.
- Ifeacho S, Aung T, Akinsola M. Kikuchi–Fujimoto disease: a case report and review of the literature. Cases J 2008;1:187.
- Atarashi K, Yoshimura N, Nodera H, et al. Recurrent histiocytic necrotizing lymphadenitis (Kikuchi's disease) in an human T lymphotropic virus type I carrier. *Intern Med* 1996;35:821-5.
- Kikuchi M, Takeshita M, Eimoto T, et al. Histiocytic necrotizing lymphadenitis: clinicopathologic, immunologic, and HLA-typing study. In: Hanaoka M, Kadin M, Mikata A, editors. *Lymphoid malignancy*. New York (NY): Field and Wood; 1990. p. 251–7.

Correspondence to: Dr. Matthew D. Seftel, Section of Hematology–Oncology, Department of Internal Medicine, University of Manitoba, 675 McDermott Ave., Winnipeg MB R3E 0V9; matthew.seftel@cancercare.mb.ca